{"transactions":[{"id":53666,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"ELI LILLY & Co","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11482,"kind":"organization","name":"Shenandoah Acquisition Corp","position":2,"cik":"0001983165","reported_name":"Shenandoah Acquisition Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-14T20:30:10.000Z","date":"2023-08-11","kind":"purchase","planned":false,"acquired":true,"shares":1718493,"price":14.92,"value":25639915.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Eli Lilly and Company (\"Lilly\") and its wholly-owned subsidiary, Shenandoah Acquisition Corporation (\"Purchaser\"), entered into an Agreement and Plan of Merger, dated as of June 28, 2023 (the \"Merger Agreement\"), with Sigilon Therapeutics, Inc. (the \"Issuer\"), pursuant to which Purchaser commenced a tender offer (as amended and supplemented from time to time, the \"Offer\") to purchase all the outstanding shares of common stock, par value $0.001 per share (the \"Shares\"), of the Issuer in exchange for (a) $14.92 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right (\"CVR\") per Share,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the contractual right to receive contingent payments of up to $111.64 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of August 10, 2023, by and among Lilly, Purchaser, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"kind","element":"transactionCoding","label":"F3","text":"As of one minute past 11:59 p.m., Eastern Time, on August 9, 2023 (the \"Expiration Time\"), when the Offer expired, 1,718,493 Shares were validly tendered and not validly withdrawn in accordance with the terms of the Offer. On August 11, 2023, Purchaser accepted for payment all Shares validly tendered and not validly withdrawn pursuant to the Offer prior to the Expiration Time."},{"field":"shares","element":"transactionShares","label":"F1","text":"Eli Lilly and Company (\"Lilly\") and its wholly-owned subsidiary, Shenandoah Acquisition Corporation (\"Purchaser\"), entered into an Agreement and Plan of Merger, dated as of June 28, 2023 (the \"Merger Agreement\"), with Sigilon Therapeutics, Inc. (the \"Issuer\"), pursuant to which Purchaser commenced a tender offer (as amended and supplemented from time to time, the \"Offer\") to purchase all the outstanding shares of common stock, par value $0.001 per share (the \"Shares\"), of the Issuer in exchange for (a) $14.92 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right (\"CVR\") per Share,"},{"field":"shares","element":"transactionShares","label":"F2","text":"(continued from footnote 1) which represents the contractual right to receive contingent payments of up to $111.64 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of August 10, 2023, by and among Lilly, Purchaser, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"shares","element":"transactionShares","label":"F3","text":"As of one minute past 11:59 p.m., Eastern Time, on August 9, 2023 (the \"Expiration Time\"), when the Offer expired, 1,718,493 Shares were validly tendered and not validly withdrawn in accordance with the terms of the Offer. On August 11, 2023, Purchaser accepted for payment all Shares validly tendered and not validly withdrawn pursuant to the Offer prior to the Expiration Time."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Eli Lilly and Company (\"Lilly\") and its wholly-owned subsidiary, Shenandoah Acquisition Corporation (\"Purchaser\"), entered into an Agreement and Plan of Merger, dated as of June 28, 2023 (the \"Merger Agreement\"), with Sigilon Therapeutics, Inc. (the \"Issuer\"), pursuant to which Purchaser commenced a tender offer (as amended and supplemented from time to time, the \"Offer\") to purchase all the outstanding shares of common stock, par value $0.001 per share (the \"Shares\"), of the Issuer in exchange for (a) $14.92 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right (\"CVR\") per Share,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the contractual right to receive contingent payments of up to $111.64 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of August 10, 2023, by and among Lilly, Purchaser, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of one minute past 11:59 p.m., Eastern Time, on August 9, 2023 (the \"Expiration Time\"), when the Offer expired, 1,718,493 Shares were validly tendered and not validly withdrawn in accordance with the terms of the Offer. On August 11, 2023, Purchaser accepted for payment all Shares validly tendered and not validly withdrawn pursuant to the Offer prior to the Expiration Time."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Eli Lilly and Company (\"Lilly\") and its wholly-owned subsidiary, Shenandoah Acquisition Corporation (\"Purchaser\"), entered into an Agreement and Plan of Merger, dated as of June 28, 2023 (the \"Merger Agreement\"), with Sigilon Therapeutics, Inc. (the \"Issuer\"), pursuant to which Purchaser commenced a tender offer (as amended and supplemented from time to time, the \"Offer\") to purchase all the outstanding shares of common stock, par value $0.001 per share (the \"Shares\"), of the Issuer in exchange for (a) $14.92 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right (\"CVR\") per Share,"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) which represents the contractual right to receive contingent payments of up to $111.64 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of August 10, 2023, by and among Lilly, Purchaser, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"As of one minute past 11:59 p.m., Eastern Time, on August 9, 2023 (the \"Expiration Time\"), when the Offer expired, 1,718,493 Shares were validly tendered and not validly withdrawn in accordance with the terms of the Offer. On August 11, 2023, Purchaser accepted for payment all Shares validly tendered and not validly withdrawn pursuant to the Offer prior to the Expiration Time."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Following consummation of the Offer, on August 11, 2023, Lilly completed its acquisition of the Issuer pursuant to the terms of the Merger Agreement through the merger of Purchaser with and into the Issuer, and without a meeting of the stockholders of the Issuer in accordance with Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer surviving such merger as a wholly-owned subsidiary of Lilly. As a result of the merger, Lilly received an aggregate of 100 newly issued shares of common stock, $0.0001 par value per share (the \"New Shares\"), of the Issuer, which represent all of the Issuer's issued and outstanding New Shares."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0000899243-23-018115","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000089924323018115/doc4.xml","form_type":"4"}},{"id":61100,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":11575,"kind":"organization","name":"Kearny Acquisition Corp","position":1,"cik":"0001951111","reported_name":"Kearny Acquisition Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":2,"cik":"0000059478","reported_name":"ELI LILLY & Co","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-01T21:10:12.000Z","date":"2022-11-30","kind":"purchase","acquired":true,"shares":29992668,"price":12.5,"value":374908350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Eli Lilly and Company (\"Lilly\") and its wholly-owned subsidiary, Kearny Acquisition Corporation (\"Purchaser\"), entered into an Agreement and Plan of Merger, dated as of October 17, 2022 (the \"Merger Agreement\"), with Akouos, Inc. (the \"Issuer\"), pursuant to which Purchaser commenced a tender offer (as amended and supplemented from time to time, the \"Offer\") to purchase all the outstanding shares of common stock, par value $0.0001 per share (the \"Shares\"), of the Issuer in exchange for (a) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right (\"CVR\") per Share,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Lilly, Purchaser, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"kind","element":"transactionCoding","label":"F3","text":"As of one minute past 11:59 p.m., Eastern Time, on November 29, 2022 (the \"Expiration Time\"), when the Offer expired, approximately 29,992,668 Shares were validly tendered and not validly withdrawn in accordance with the terms of the Offer. On November 30, 2022, Purchaser accepted for payment all Shares validly tendered and not validly withdrawn pursuant to the Offer prior to the Expiration Time."},{"field":"shares","element":"transactionShares","label":"F1","text":"Eli Lilly and Company (\"Lilly\") and its wholly-owned subsidiary, Kearny Acquisition Corporation (\"Purchaser\"), entered into an Agreement and Plan of Merger, dated as of October 17, 2022 (the \"Merger Agreement\"), with Akouos, Inc. (the \"Issuer\"), pursuant to which Purchaser commenced a tender offer (as amended and supplemented from time to time, the \"Offer\") to purchase all the outstanding shares of common stock, par value $0.0001 per share (the \"Shares\"), of the Issuer in exchange for (a) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right (\"CVR\") per Share,"},{"field":"shares","element":"transactionShares","label":"F2","text":"(continued from footnote 1) which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Lilly, Purchaser, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"shares","element":"transactionShares","label":"F3","text":"As of one minute past 11:59 p.m., Eastern Time, on November 29, 2022 (the \"Expiration Time\"), when the Offer expired, approximately 29,992,668 Shares were validly tendered and not validly withdrawn in accordance with the terms of the Offer. On November 30, 2022, Purchaser accepted for payment all Shares validly tendered and not validly withdrawn pursuant to the Offer prior to the Expiration Time."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Eli Lilly and Company (\"Lilly\") and its wholly-owned subsidiary, Kearny Acquisition Corporation (\"Purchaser\"), entered into an Agreement and Plan of Merger, dated as of October 17, 2022 (the \"Merger Agreement\"), with Akouos, Inc. (the \"Issuer\"), pursuant to which Purchaser commenced a tender offer (as amended and supplemented from time to time, the \"Offer\") to purchase all the outstanding shares of common stock, par value $0.0001 per share (the \"Shares\"), of the Issuer in exchange for (a) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right (\"CVR\") per Share,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Lilly, Purchaser, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of one minute past 11:59 p.m., Eastern Time, on November 29, 2022 (the \"Expiration Time\"), when the Offer expired, approximately 29,992,668 Shares were validly tendered and not validly withdrawn in accordance with the terms of the Offer. On November 30, 2022, Purchaser accepted for payment all Shares validly tendered and not validly withdrawn pursuant to the Offer prior to the Expiration Time."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Eli Lilly and Company (\"Lilly\") and its wholly-owned subsidiary, Kearny Acquisition Corporation (\"Purchaser\"), entered into an Agreement and Plan of Merger, dated as of October 17, 2022 (the \"Merger Agreement\"), with Akouos, Inc. (the \"Issuer\"), pursuant to which Purchaser commenced a tender offer (as amended and supplemented from time to time, the \"Offer\") to purchase all the outstanding shares of common stock, par value $0.0001 per share (the \"Shares\"), of the Issuer in exchange for (a) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right (\"CVR\") per Share,"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Lilly, Purchaser, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"As of one minute past 11:59 p.m., Eastern Time, on November 29, 2022 (the \"Expiration Time\"), when the Offer expired, approximately 29,992,668 Shares were validly tendered and not validly withdrawn in accordance with the terms of the Offer. On November 30, 2022, Purchaser accepted for payment all Shares validly tendered and not validly withdrawn pursuant to the Offer prior to the Expiration Time."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Following consummation of the Offer, on December 1, 2022, Lilly completed its acquisition of the Issuer pursuant to the terms of the Merger Agreement through the merger of Purchaser with and into the Issuer, and without a meeting of the stockholders of the Issuer in accordance with Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer surviving such merger as a wholly-owned subsidiary of Lilly. As a result of the merger, Lilly received an aggregate of 100 newly issued shares of common stock, $0.00001 par value per share (the \"New Shares\"), of the Issuer, which represent all of the Issuer's issued and outstanding New Shares."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0000899243-22-037279","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000089924322037279/doc4.xml","form_type":"4"}},{"id":95059,"issuer":{"id":11821,"kind":"organization","name":"Prevail Therapeutics Inc.","symbol":"PRVL"},"owners":[{"id":11822,"kind":"organization","name":"Tyto Acquisition Corp","position":1,"cik":"0001836675","reported_name":"Tyto Acquisition Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":2,"cik":"0000059478","reported_name":"ELI LILLY & Co","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-22T21:26:04.000Z","date":"2021-01-22","kind":"purchase","acquired":true,"shares":34284789,"price":22.5,"value":771407752.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Eli Lilly and Company (\"Lilly\") and its wholly-owned subsidiary, Tyto Acquisition Corporation (\"Purchaser\"), entered into an Agreement and Plan of Merger, dated as of December 14, 2020 (the \"Merger Agreement\"), with Prevail Therapeutics Inc. (the \"Issuer\"), pursuant to which Purchaser commenced a cash tender offer (as amended from time to time in accordance with the terms of the Merger Agreement, the \"Offer\") to purchase all the outstanding shares of common stock, par value $0.0001 per share, of the Issuer (\"Issuer Common Stock\"), at a price per share of Issuer Common Stock of (a) $22.50 per Share, net to the seller in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right (a \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which CVR represents the contractual right to receive a contingent payment of up to $4.00 per share, net to the seller in cash, without interest, which amount (or such lesser amount as determined in accordance with the terms and conditions of such contingent value right) will become payable, if at all, if a specified milestone is achieved prior to December 1, 2028, on the terms and subject to the conditions set forth in the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F3","text":"As of one minute after 11:59 PM, Eastern time, on January 21, 2021, when the Offer expired, approximately 27,374,689 Shares were validly tendered and not validly withdrawn in accordance with the terms of the Offer. On January 22, 2021, Purchaser accepted for payment, and expects to as soon as practicable pay for, all Shares validly tendered and not validly withdrawn prior to the expiration of the Offer. Pursuant to the Merger Agreement, on January 22, 2021, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware and without any stockholder vote, with Issuer surviving as a wholly-owned subsidiary of Lilly (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Eli Lilly and Company (\"Lilly\") and its wholly-owned subsidiary, Tyto Acquisition Corporation (\"Purchaser\"), entered into an Agreement and Plan of Merger, dated as of December 14, 2020 (the \"Merger Agreement\"), with Prevail Therapeutics Inc. (the \"Issuer\"), pursuant to which Purchaser commenced a cash tender offer (as amended from time to time in accordance with the terms of the Merger Agreement, the \"Offer\") to purchase all the outstanding shares of common stock, par value $0.0001 per share, of the Issuer (\"Issuer Common Stock\"), at a price per share of Issuer Common Stock of (a) $22.50 per Share, net to the seller in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right (a \"CVR\"),"},{"field":"shares","element":"transactionShares","label":"F2","text":"(continued from footnote 1) which CVR represents the contractual right to receive a contingent payment of up to $4.00 per share, net to the seller in cash, without interest, which amount (or such lesser amount as determined in accordance with the terms and conditions of such contingent value right) will become payable, if at all, if a specified milestone is achieved prior to December 1, 2028, on the terms and subject to the conditions set forth in the Merger Agreement."},{"field":"shares","element":"transactionShares","label":"F3","text":"As of one minute after 11:59 PM, Eastern time, on January 21, 2021, when the Offer expired, approximately 27,374,689 Shares were validly tendered and not validly withdrawn in accordance with the terms of the Offer. On January 22, 2021, Purchaser accepted for payment, and expects to as soon as practicable pay for, all Shares validly tendered and not validly withdrawn prior to the expiration of the Offer. Pursuant to the Merger Agreement, on January 22, 2021, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware and without any stockholder vote, with Issuer surviving as a wholly-owned subsidiary of Lilly (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F4","text":"At the effective time of the Merger (the \"Effective Time\"), and as a result of the Merger, all outstanding shares of capital stock of Purchaser issued and outstanding immediately prior to the Effective Time were converted into an aggregate of 100 shares of newly and validly issued, fully paid and non-assessable shares of common stock of Issuer, as the surviving corporation. Consequently, following the consummation of the Merger on January 22, 2021, Lilly became the owner of 100 shares of common stock of Issuer, representing the only outstanding capital of Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Eli Lilly and Company (\"Lilly\") and its wholly-owned subsidiary, Tyto Acquisition Corporation (\"Purchaser\"), entered into an Agreement and Plan of Merger, dated as of December 14, 2020 (the \"Merger Agreement\"), with Prevail Therapeutics Inc. (the \"Issuer\"), pursuant to which Purchaser commenced a cash tender offer (as amended from time to time in accordance with the terms of the Merger Agreement, the \"Offer\") to purchase all the outstanding shares of common stock, par value $0.0001 per share, of the Issuer (\"Issuer Common Stock\"), at a price per share of Issuer Common Stock of (a) $22.50 per Share, net to the seller in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right (a \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which CVR represents the contractual right to receive a contingent payment of up to $4.00 per share, net to the seller in cash, without interest, which amount (or such lesser amount as determined in accordance with the terms and conditions of such contingent value right) will become payable, if at all, if a specified milestone is achieved prior to December 1, 2028, on the terms and subject to the conditions set forth in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of one minute after 11:59 PM, Eastern time, on January 21, 2021, when the Offer expired, approximately 27,374,689 Shares were validly tendered and not validly withdrawn in accordance with the terms of the Offer. On January 22, 2021, Purchaser accepted for payment, and expects to as soon as practicable pay for, all Shares validly tendered and not validly withdrawn prior to the expiration of the Offer. Pursuant to the Merger Agreement, on January 22, 2021, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware and without any stockholder vote, with Issuer surviving as a wholly-owned subsidiary of Lilly (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the effective time of the Merger (the \"Effective Time\"), and as a result of the Merger, all outstanding shares of capital stock of Purchaser issued and outstanding immediately prior to the Effective Time were converted into an aggregate of 100 shares of newly and validly issued, fully paid and non-assessable shares of common stock of Issuer, as the surviving corporation. Consequently, following the consummation of the Merger on January 22, 2021, Lilly became the owner of 100 shares of common stock of Issuer, representing the only outstanding capital of Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Eli Lilly and Company (\"Lilly\") and its wholly-owned subsidiary, Tyto Acquisition Corporation (\"Purchaser\"), entered into an Agreement and Plan of Merger, dated as of December 14, 2020 (the \"Merger Agreement\"), with Prevail Therapeutics Inc. (the \"Issuer\"), pursuant to which Purchaser commenced a cash tender offer (as amended from time to time in accordance with the terms of the Merger Agreement, the \"Offer\") to purchase all the outstanding shares of common stock, par value $0.0001 per share, of the Issuer (\"Issuer Common Stock\"), at a price per share of Issuer Common Stock of (a) $22.50 per Share, net to the seller in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right (a \"CVR\"),"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) which CVR represents the contractual right to receive a contingent payment of up to $4.00 per share, net to the seller in cash, without interest, which amount (or such lesser amount as determined in accordance with the terms and conditions of such contingent value right) will become payable, if at all, if a specified milestone is achieved prior to December 1, 2028, on the terms and subject to the conditions set forth in the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"As of one minute after 11:59 PM, Eastern time, on January 21, 2021, when the Offer expired, approximately 27,374,689 Shares were validly tendered and not validly withdrawn in accordance with the terms of the Offer. On January 22, 2021, Purchaser accepted for payment, and expects to as soon as practicable pay for, all Shares validly tendered and not validly withdrawn prior to the expiration of the Offer. Pursuant to the Merger Agreement, on January 22, 2021, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware and without any stockholder vote, with Issuer surviving as a wholly-owned subsidiary of Lilly (the \"Merger\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"At the effective time of the Merger (the \"Effective Time\"), and as a result of the Merger, all outstanding shares of capital stock of Purchaser issued and outstanding immediately prior to the Effective Time were converted into an aggregate of 100 shares of newly and validly issued, fully paid and non-assessable shares of common stock of Issuer, as the surviving corporation. Consequently, following the consummation of the Merger on January 22, 2021, Lilly became the owner of 100 shares of common stock of Issuer, representing the only outstanding capital of Issuer."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0000899243-21-002923","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000089924321002923/doc4.xml","form_type":"4"}},{"id":97052,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"ELI LILLY & Co","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-12-10T22:00:52.000Z","date":"2020-12-08","kind":"exercise","acquired":false,"shares":888888,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A-3 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock without payment or further consideration. There was no expiration date for the Preferred Stock. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A-3 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock without payment or further consideration. There was no expiration date for the Preferred Stock. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A-3 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock without payment or further consideration. There was no expiration date for the Preferred Stock. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A-3 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock without payment or further consideration. There was no expiration date for the Preferred Stock. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A-3 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock without payment or further consideration. There was no expiration date for the Preferred Stock. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":888888},"source":{"system":"sec-edgar","filing":"0000059478-20-000187","document":"wf-form4_160763763834444.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947820000187/wf-form4_160763763834444.xml","form_type":"4"}},{"id":97051,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"ELI LILLY & Co","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-3 Convertible Preferred Stock","published_at":"2020-12-10T22:00:52.000Z","date":"2020-12-08","kind":"exercise","acquired":false,"shares":1555555,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A-3 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock without payment or further consideration. There was no expiration date for the Preferred Stock. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A-3 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock without payment or further consideration. There was no expiration date for the Preferred Stock. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A-3 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock without payment or further consideration. There was no expiration date for the Preferred Stock. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A-3 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock without payment or further consideration. There was no expiration date for the Preferred Stock. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A-3 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock without payment or further consideration. There was no expiration date for the Preferred Stock. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1555555},"source":{"system":"sec-edgar","filing":"0000059478-20-000187","document":"wf-form4_160763763834444.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947820000187/wf-form4_160763763834444.xml","form_type":"4"}},{"id":97050,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"ELI LILLY & Co","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-10T22:00:52.000Z","date":"2020-12-08","kind":"purchase","acquired":true,"shares":300000,"price":18,"value":5400000.0,"ownership":{"direct":true},"balance_after":2744443,"source":{"system":"sec-edgar","filing":"0000059478-20-000187","document":"wf-form4_160763763834444.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947820000187/wf-form4_160763763834444.xml","form_type":"4"}},{"id":97049,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"ELI LILLY & Co","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-10T22:00:52.000Z","date":"2020-12-08","kind":"exercise","acquired":true,"shares":2444443,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A-3 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock without payment or further consideration. There was no expiration date for the Preferred Stock. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A-3 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock without payment or further consideration. There was no expiration date for the Preferred Stock. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."}],"balance_after":2444443,"source":{"system":"sec-edgar","filing":"0000059478-20-000187","document":"wf-form4_160763763834444.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947820000187/wf-form4_160763763834444.xml","form_type":"4"}},{"id":103879,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"ELI LILLY & Co","relationship":{"ten_percent_owner":true}}],"security":"Series C Preferred Stock","published_at":"2020-06-16T22:15:55.000Z","date":"2020-06-16","kind":"exercise","acquired":false,"shares":4576342,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2169396},"source":{"system":"sec-edgar","filing":"0001140361-20-013983","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000114036120013983/form4.xml","form_type":"4"}},{"id":103878,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"ELI LILLY & Co","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-06-16T22:15:55.000Z","date":"2020-06-16","kind":"exercise","acquired":true,"shares":2169396,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering."}],"balance_after":2169396,"source":{"system":"sec-edgar","filing":"0001140361-20-013983","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000114036120013983/form4.xml","form_type":"4"}},{"id":107327,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":11897,"kind":"organization","name":"Bald Eagle Acquisition Corp","position":1,"cik":"0001799399","reported_name":"Bald Eagle Acquisition Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":2,"cik":"0000059478","reported_name":"ELI LILLY & Co","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-20T21:00:28.000Z","date":"2020-02-20","kind":"purchase","acquired":true,"shares":40926025,"price":18.75,"value":767362968.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Eli Lilly and Company (\"Lilly\") and its wholly-owned subsidiary, Bald Eagle Acquisition Corporation (\"Purchaser\"), entered into an Agreement and Plan of Merger, dated as of January 10, 2020 (the \"Merger Agreement\"), with Dermira, Inc. (the \"Issuer\"), pursuant to which Purchaser commenced a cash tender offer (as amended from time to time in accordance with the terms of the Merger Agreement, the \"Offer\") to purchase all the outstanding shares of common stock, par value $0.001 per share, of the Issuer (\"Issuer Common Stock\"), at a price per share of Issuer Common Stock of $18.75 (such amount or, as the Offer is amended in accordance with the terms of the Merger Agreement and a different amount per share is paid pursuant to the Offer, such different amount, the \"Offer Price\"), net to the seller in cash, without interest, on the terms and subject to the conditions set forth in the Merger Agreement. As a result of the Offer, Purchaser acquired 40,926,025 shares of Issuer Common Stock."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects all of the outstanding shares of the Issuer not tendered in the Offer, which may be deemed to have been acquired by Lilly and Purchaser pursuant to the consummation of the transactions contemplated by the Merger Agreement."},{"field":"shares","element":"transactionShares","label":"F1","text":"Eli Lilly and Company (\"Lilly\") and its wholly-owned subsidiary, Bald Eagle Acquisition Corporation (\"Purchaser\"), entered into an Agreement and Plan of Merger, dated as of January 10, 2020 (the \"Merger Agreement\"), with Dermira, Inc. (the \"Issuer\"), pursuant to which Purchaser commenced a cash tender offer (as amended from time to time in accordance with the terms of the Merger Agreement, the \"Offer\") to purchase all the outstanding shares of common stock, par value $0.001 per share, of the Issuer (\"Issuer Common Stock\"), at a price per share of Issuer Common Stock of $18.75 (such amount or, as the Offer is amended in accordance with the terms of the Merger Agreement and a different amount per share is paid pursuant to the Offer, such different amount, the \"Offer Price\"), net to the seller in cash, without interest, on the terms and subject to the conditions set forth in the Merger Agreement. As a result of the Offer, Purchaser acquired 40,926,025 shares of Issuer Common Stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects all of the outstanding shares of the Issuer not tendered in the Offer, which may be deemed to have been acquired by Lilly and Purchaser pursuant to the consummation of the transactions contemplated by the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Eli Lilly and Company (\"Lilly\") and its wholly-owned subsidiary, Bald Eagle Acquisition Corporation (\"Purchaser\"), entered into an Agreement and Plan of Merger, dated as of January 10, 2020 (the \"Merger Agreement\"), with Dermira, Inc. (the \"Issuer\"), pursuant to which Purchaser commenced a cash tender offer (as amended from time to time in accordance with the terms of the Merger Agreement, the \"Offer\") to purchase all the outstanding shares of common stock, par value $0.001 per share, of the Issuer (\"Issuer Common Stock\"), at a price per share of Issuer Common Stock of $18.75 (such amount or, as the Offer is amended in accordance with the terms of the Merger Agreement and a different amount per share is paid pursuant to the Offer, such different amount, the \"Offer Price\"), net to the seller in cash, without interest, on the terms and subject to the conditions set forth in the Merger Agreement. As a result of the Offer, Purchaser acquired 40,926,025 shares of Issuer Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects all of the outstanding shares of the Issuer not tendered in the Offer, which may be deemed to have been acquired by Lilly and Purchaser pursuant to the consummation of the transactions contemplated by the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Effective on February 20, 2020, Purchaser was merged with and into the Issuer, with the Issuer surviving the Merger as a wholly-owned subsidiary of Lilly (the \"Merger\"). As a result of the Merger, all of the outstanding shares of Issuer Common Stock (other than those owned by Lilly or Purchaser) were cancelled and converted into the right to receive the merger consideration under the Merger Agreement.  Following and as a result of the Merger, Lilly owned 100 shares of Issuer Common Stock, which represents all of the outstanding shares of common stock of the Issuer."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0000899243-20-005280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000089924320005280/doc4.xml","form_type":"4"}},{"id":118661,"issuer":{"id":3457,"kind":"organization","name":"Elanco Animal Health Inc","symbol":"ELAN"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-03-11T12:03:18.000Z","date":"2019-03-11","kind":"disposition_to_issuer","acquired":false,"shares":293290000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Eli Lilly and Company (\"Lilly\") disposed of 293,290,000 shares of common stock of the Issuer in exchange for 65,000,775 shares of Lilly common stock pursuant to a registered exchange offer to Lilly's common shareholders. The final exchange ratio was 4.5121 shares of Issuer common stock per share of Lilly common stock accepted in the exchange offer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-19-013734","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000110465919013734/a4.xml","form_type":"4"}},{"id":120663,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-04T21:36:07.000Z","date":"2019-01-31","kind":"sale","acquired":false,"shares":250000,"price":16,"value":4000000.0,"ownership":{"direct":true},"balance_after":2898647,"source":{"system":"sec-edgar","filing":"0000059478-19-000030","document":"wf-form4_154931615186460.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947819000030/wf-form4_154931615186460.xml","form_type":"4"}},{"id":123189,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-08T16:34:49.000Z","date":"2018-11-06","kind":"sale","acquired":false,"shares":700000,"price":14,"value":9800000.0,"ownership":{"direct":true},"balance_after":3148647,"source":{"system":"sec-edgar","filing":"0000059478-18-000260","document":"wf-form4_154169487351750.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000260/wf-form4_154169487351750.xml","form_type":"4"}},{"id":124224,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-26T18:50:01.000Z","date":"2018-09-24","kind":"sale","acquired":false,"shares":2027,"price":16.36,"value":33161.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $16.32 to $16.45. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3848647,"source":{"system":"sec-edgar","filing":"0000059478-18-000238","document":"wf-form4_153798778465789.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000238/wf-form4_153798778465789.xml","form_type":"4"}},{"id":124339,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T20:50:57.000Z","date":"2018-09-18","kind":"sale","acquired":false,"shares":6870,"price":14.56,"value":100027.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $14.40 to $14.85. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3850674,"source":{"system":"sec-edgar","filing":"0000059478-18-000232","document":"wf-form4_153747663888132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000232/wf-form4_153747663888132.xml","form_type":"4"}},{"id":124417,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-18T23:30:07.000Z","date":"2018-09-17","kind":"sale","acquired":false,"shares":6865,"price":14.58,"value":100091.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $14.50 to $14.86. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3857544,"source":{"system":"sec-edgar","filing":"0000059478-18-000222","document":"wf-form4_153731339170921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000222/wf-form4_153731339170921.xml","form_type":"4"}},{"id":124416,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-18T23:30:07.000Z","date":"2018-09-14","kind":"sale","acquired":false,"shares":9009,"price":14.58,"value":131351.22,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $14.43 to $14.66. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3864409,"source":{"system":"sec-edgar","filing":"0000059478-18-000222","document":"wf-form4_153731339170921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000222/wf-form4_153731339170921.xml","form_type":"4"}},{"id":124460,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-14T19:34:13.000Z","date":"2018-09-13","kind":"sale","acquired":false,"shares":20900,"price":14.32,"value":299288.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $14.25 to $14.41. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3873418,"source":{"system":"sec-edgar","filing":"0000059478-18-000220","document":"wf-form4_153695363698223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000220/wf-form4_153695363698223.xml","form_type":"4"}},{"id":124459,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-14T19:34:13.000Z","date":"2018-09-12","kind":"sale","acquired":false,"shares":10059,"price":14.83,"value":149174.97,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $14.25 to $15.52. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3894318,"source":{"system":"sec-edgar","filing":"0000059478-18-000220","document":"wf-form4_153695363698223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000220/wf-form4_153695363698223.xml","form_type":"4"}},{"id":124563,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-12T20:39:51.000Z","date":"2018-09-11","kind":"sale","acquired":false,"shares":11277,"price":14.87,"value":167688.99,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $14.29 to $15.29. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3904377,"source":{"system":"sec-edgar","filing":"0000059478-18-000218","document":"wf-form4_153678477558447.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000218/wf-form4_153678477558447.xml","form_type":"4"}},{"id":124562,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-12T20:39:51.000Z","date":"2018-09-10","kind":"sale","acquired":false,"shares":4500,"price":14.44,"value":64980.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $14.25 to $14.61. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3915654,"source":{"system":"sec-edgar","filing":"0000059478-18-000218","document":"wf-form4_153678477558447.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000218/wf-form4_153678477558447.xml","form_type":"4"}},{"id":124804,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-04T19:38:13.000Z","date":"2018-08-31","kind":"sale","acquired":false,"shares":700,"price":14.26,"value":9982.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $14.25 to $14.27. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3920154,"source":{"system":"sec-edgar","filing":"0000059478-18-000212","document":"wf-form4_153608987633805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000212/wf-form4_153608987633805.xml","form_type":"4"}},{"id":124823,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-31T16:40:57.000Z","date":"2018-08-30","kind":"sale","acquired":false,"shares":3440,"price":14.35,"value":49364.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $14.25 to $14.50. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3920854,"source":{"system":"sec-edgar","filing":"0000059478-18-000210","document":"wf-form4_153573363887839.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000210/wf-form4_153573363887839.xml","form_type":"4"}},{"id":124822,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-31T16:40:57.000Z","date":"2018-08-29","kind":"sale","acquired":false,"shares":2312,"price":14.26,"value":32969.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $14.25 to $14.30. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3924294,"source":{"system":"sec-edgar","filing":"0000059478-18-000210","document":"wf-form4_153573363887839.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000210/wf-form4_153573363887839.xml","form_type":"4"}},{"id":125543,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-16T19:34:47.000Z","date":"2018-08-14","kind":"sale","acquired":false,"shares":3000,"price":14.28,"value":42840.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $14.25 to $14.33. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3926606,"source":{"system":"sec-edgar","filing":"0000059478-18-000202","document":"wf-form4_153444807156845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000202/wf-form4_153444807156845.xml","form_type":"4"}},{"id":125648,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-14T21:04:42.000Z","date":"2018-08-13","kind":"sale","acquired":false,"shares":4531,"price":14.33,"value":64929.23,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $14.25 to $14.64. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3929606,"source":{"system":"sec-edgar","filing":"0000059478-18-000200","document":"wf-form4_153428066308523.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000200/wf-form4_153428066308523.xml","form_type":"4"}},{"id":125647,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-14T21:04:42.000Z","date":"2018-08-10","kind":"sale","acquired":false,"shares":1898,"price":14.28,"value":27103.44,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $14.25 to $14.38. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3934137,"source":{"system":"sec-edgar","filing":"0000059478-18-000200","document":"wf-form4_153428066308523.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000200/wf-form4_153428066308523.xml","form_type":"4"}},{"id":125679,"issuer":{"id":6392,"kind":"organization","name":"CYPHERPUNK TECHNOLOGIES INC.","symbol":"CYPH"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2018-08-13T21:30:57.000Z","date":"2018-07-30","kind":"grant","acquired":true,"shares":331221,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":331221,"derivative":{"exercise_price":6.085,"exercise_date":"2018-07-30","expiration_date":"2024-11-14","underlying":"Common Stock, $0.001 par value per share","underlying_shares":331221},"source":{"system":"sec-edgar","filing":"0000059478-18-000198","document":"wf-form4_153419584098663.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000198/wf-form4_153419584098663.xml","form_type":"4"}},{"id":126019,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-07T19:16:24.000Z","date":"2018-08-03","kind":"sale","acquired":false,"shares":1650,"price":13.55,"value":22357.5,"ownership":{"direct":true},"balance_after":3936035,"source":{"system":"sec-edgar","filing":"0000059478-18-000196","document":"wf-form4_153366936740123.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000196/wf-form4_153366936740123.xml","form_type":"4"}},{"id":126283,"issuer":{"id":12038,"kind":"organization","name":"Zymeworks BC Inc.","symbol":"ZYME"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-03T19:53:07.000Z","date":"2018-08-02","kind":"sale","acquired":false,"shares":19400,"price":13.31,"value":258214.0,"ownership":{"direct":true},"balance_after":3937685,"source":{"system":"sec-edgar","filing":"0000059478-18-000194","document":"wf-form4_153332597193355.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947818000194/wf-form4_153332597193355.xml","form_type":"4"}},{"id":142735,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12305,"kind":"organization","name":"ProCar Acquisition Corp","position":2,"cik":"0001695312","reported_name":"ProCar Acquisition Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2017-03-01T22:02:45.000Z","date":"2017-03-01","kind":"other","acquired":true,"shares":19285108,"price":46.5,"value":896757522.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 1, 2017, Eli Lilly and Company (\"Parent\") and ProCar Acquisition Corporation (\"Merger Sub\") completed the transactions contemplated by the Agreement and Plan of Merger, dated as of January 17, 2017, by and among CoLucid Pharmaceuticals, Inc. (the \"Issuer\"), Parent and Merger Sub (the \"Merger Agreement\").  Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer surviving the Merger as a wholly-owned subsidiary of Parent (the \"Surviving Corporation\").  At the effective time of the Merger, the outstanding shares of common stock of Merger Sub were converted into and became shares of the Surviving Corporation."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 1, 2017, Eli Lilly and Company (\"Parent\") and ProCar Acquisition Corporation (\"Merger Sub\") completed the transactions contemplated by the Agreement and Plan of Merger, dated as of January 17, 2017, by and among CoLucid Pharmaceuticals, Inc. (the \"Issuer\"), Parent and Merger Sub (the \"Merger Agreement\").  Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer surviving the Merger as a wholly-owned subsidiary of Parent (the \"Surviving Corporation\").  At the effective time of the Merger, the outstanding shares of common stock of Merger Sub were converted into and became shares of the Surviving Corporation."},{"field":"shares","element":"transactionShares","label":"F1","text":"On March 1, 2017, Eli Lilly and Company (\"Parent\") and ProCar Acquisition Corporation (\"Merger Sub\") completed the transactions contemplated by the Agreement and Plan of Merger, dated as of January 17, 2017, by and among CoLucid Pharmaceuticals, Inc. (the \"Issuer\"), Parent and Merger Sub (the \"Merger Agreement\").  Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer surviving the Merger as a wholly-owned subsidiary of Parent (the \"Surviving Corporation\").  At the effective time of the Merger, the outstanding shares of common stock of Merger Sub were converted into and became shares of the Surviving Corporation."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0000899243-17-005803","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000089924317005803/doc4.xml","form_type":"4"}},{"id":153844,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12398,"kind":"person","name":"Shanafelt Armen","position":3,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-04-14T23:35:05.000Z","date":"2016-04-12","kind":"exercise","acquired":true,"shares":2010924,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by fund"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). LV Management Group LLC (the \"Management Company\") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This line item is being re-reported in order to gain access to the filing system. This Form is being amended to include Reporting Owners, Lilly Ventures Fund I LLC, and Dr. Shanafelt Armen as beneficial owners of the shares reported in the Form 4, previously filed by Eli Lilly and Company on April 14, 2016."}],"balance_after":2068543,"source":{"system":"sec-edgar","filing":"0000059478-16-000342","document":"wf-form4a_146067689367014.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947816000342/wf-form4a_146067689367014.xml","form_type":"4/A","original_submission_date":"2016-04-14"}},{"id":153848,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2016-04-14T22:41:54.000Z","date":"2016-04-12","kind":"exercise","acquired":false,"shares":1120448,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by fund"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). LV Management Group LLC (the \"Management Company\") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1120448},"source":{"system":"sec-edgar","filing":"0000059478-16-000339","document":"wf-form4_146067370280526.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947816000339/wf-form4_146067370280526.xml","form_type":"4"}},{"id":153847,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2016-04-14T22:41:54.000Z","date":"2016-04-12","kind":"exercise","acquired":false,"shares":890476,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by fund"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). LV Management Group LLC (the \"Management Company\") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":890476},"source":{"system":"sec-edgar","filing":"0000059478-16-000339","document":"wf-form4_146067370280526.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947816000339/wf-form4_146067370280526.xml","form_type":"4"}},{"id":153846,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-04-14T22:41:54.000Z","date":"2016-04-12","kind":"purchase","acquired":true,"shares":500000,"price":10,"value":5000000.0,"ownership":{"direct":false,"nature":"by fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). LV Management Group LLC (the \"Management Company\") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein."}],"balance_after":2568543,"source":{"system":"sec-edgar","filing":"0000059478-16-000339","document":"wf-form4_146067370280526.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947816000339/wf-form4_146067370280526.xml","form_type":"4"}},{"id":153845,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-04-14T22:41:54.000Z","date":"2016-04-12","kind":"exercise","acquired":true,"shares":2010924,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by fund"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). LV Management Group LLC (the \"Management Company\") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein."}],"balance_after":2068543,"source":{"system":"sec-edgar","filing":"0000059478-16-000339","document":"wf-form4_146067370280526.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947816000339/wf-form4_146067370280526.xml","form_type":"4"}},{"id":169048,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series C Preferred Stock","published_at":"2014-11-12T16:50:58.000Z","date":"2014-11-12","kind":"exercise","acquired":false,"shares":543101,"ownership":{"direct":false,"nature":"By Group"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Preferred Stock and Series C Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\").  Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":543101},"source":{"system":"sec-edgar","filing":"0001209191-14-067900","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114067900/doc4.xml","form_type":"4"}},{"id":169047,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series B Preferred Stock","published_at":"2014-11-12T16:50:58.000Z","date":"2014-11-12","kind":"exercise","acquired":false,"shares":2333955,"ownership":{"direct":false,"nature":"By Group"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Preferred Stock and Series C Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\").  Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2333955},"source":{"system":"sec-edgar","filing":"0001209191-14-067900","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114067900/doc4.xml","form_type":"4"}},{"id":169046,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock, $0.0001 par value","published_at":"2014-11-12T16:50:58.000Z","date":"2014-11-12","kind":"purchase","acquired":true,"shares":164963,"price":13.5,"value":2227000.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Lilly Ventures Fund I LLC purchased an additional 164,963 shares of Issuer's Common Stock in connection with the IPO at the offering price of $13.50 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\").  Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":3042019,"source":{"system":"sec-edgar","filing":"0001209191-14-067900","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114067900/doc4.xml","form_type":"4"}},{"id":169045,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock, $0.0001 par value","published_at":"2014-11-12T16:50:58.000Z","date":"2014-11-12","kind":"exercise","acquired":true,"shares":543101,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\").  Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":2877056,"source":{"system":"sec-edgar","filing":"0001209191-14-067900","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114067900/doc4.xml","form_type":"4"}},{"id":169044,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock, $0.0001 par value","published_at":"2014-11-12T16:50:58.000Z","date":"2014-11-12","kind":"exercise","acquired":true,"shares":2333955,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\").  Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":2333955,"source":{"system":"sec-edgar","filing":"0001209191-14-067900","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114067900/doc4.xml","form_type":"4"}},{"id":174651,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"7% Convertible Promissory Notes","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"exercise","acquired":false,"price":0,"reported_value":1084321.58,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents the number of shares of Common Stock issuable upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on February 18, 2014 through April 15, 2014, at a conversion price equal to $5.43 per share of Common Stock, which was equal to 77.5% of the Company's initial public offering price. The Notes had no expiration date and were exercisable any time after February 26, 2015 at the holder's election or automatically upon a qualified financing."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents the number of shares of Common Stock issuable upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on February 18, 2014 through April 15, 2014, at a conversion price equal to $5.43 per share of Common Stock, which was equal to 77.5% of the Company's initial public offering price. The Notes had no expiration date and were exercisable any time after February 26, 2015 at the holder's election or automatically upon a qualified financing."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Represents the number of shares of Common Stock issuable upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on February 18, 2014 through April 15, 2014, at a conversion price equal to $5.43 per share of Common Stock, which was equal to 77.5% of the Company's initial public offering price. The Notes had no expiration date and were exercisable any time after February 26, 2015 at the holder's election or automatically upon a qualified financing."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":0,"derivative":{"exercise_price":5.43,"underlying":"Common Stock","underlying_shares":199875},"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":174650,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"7% Convertible Promissory Notes","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"exercise","acquired":false,"price":0,"reported_value":1345466.43,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents the number of shares of Common Stock issued upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on August 13, 2013 through April 15, 2014, at a conversion price of $7.00 per share of Common Stock, which was the initial public offering price. The Notes had no expiration date and were exercisable any time after August 15, 2014 at the holder's election or automatically upon a qualified financing."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents the number of shares of Common Stock issued upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on August 13, 2013 through April 15, 2014, at a conversion price of $7.00 per share of Common Stock, which was the initial public offering price. The Notes had no expiration date and were exercisable any time after August 15, 2014 at the holder's election or automatically upon a qualified financing."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Represents the number of shares of Common Stock issued upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on August 13, 2013 through April 15, 2014, at a conversion price of $7.00 per share of Common Stock, which was the initial public offering price. The Notes had no expiration date and were exercisable any time after August 15, 2014 at the holder's election or automatically upon a qualified financing."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":0,"derivative":{"exercise_price":7,"underlying":"Common Stock","underlying_shares":192209},"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":174649,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"exercise","acquired":false,"shares":4340831,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":299213},"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":174648,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"exercise","acquired":false,"shares":13513513,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":931485},"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":174647,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"purchase","acquired":true,"shares":733445,"price":7,"value":5134115.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":2356227,"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":174646,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"exercise","acquired":true,"shares":199875,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the number of shares of Common Stock issuable upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on February 18, 2014 through April 15, 2014, at a conversion price equal to $5.43 per share of Common Stock, which was equal to 77.5% of the Company's initial public offering price. The Notes had no expiration date and were exercisable any time after February 26, 2015 at the holder's election or automatically upon a qualified financing."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":1622782,"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":174645,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"exercise","acquired":true,"shares":192209,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the number of shares of Common Stock issued upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on August 13, 2013 through April 15, 2014, at a conversion price of $7.00 per share of Common Stock, which was the initial public offering price. The Notes had no expiration date and were exercisable any time after August 15, 2014 at the holder's election or automatically upon a qualified financing."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":1422907,"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":174644,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"exercise","acquired":true,"shares":299213,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":1230698,"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":174643,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-04-16T00:41:02.000Z","date":"2014-04-15","kind":"exercise","acquired":true,"shares":931485,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund."}],"balance_after":931485,"source":{"system":"sec-edgar","filing":"0001209191-14-027708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919114027708/doc4.xml","form_type":"4"}},{"id":178837,"issuer":{"id":12658,"kind":"organization","name":"Receptos, Inc.","symbol":"RCPT"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2013-11-21T22:23:39.000Z","date":"2013-05-14","kind":"exercise","acquired":false,"price":0,"reported_value":5040221,"ownership":{"direct":false,"nature":"by Group"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Series A preferred stock and Series B preferred stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of common stock for every 7.5 shares of Series A preferred stock and Series B preferred stock, for no additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A preferred stock and Series B preferred stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of common stock for every 7.5 shares of Series A preferred stock and Series B preferred stock, for no additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A preferred stock and Series B preferred stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of common stock for every 7.5 shares of Series A preferred stock and Series B preferred stock, for no additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund. S. Edward Torres, is a non-managing member of the Fund and may be deemed to beneficially own the shares. Mr. Torres disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein. The attached Exhibit 99.1 lists details for each 10% and beneficial owner."}],"balance_after":0,"derivative":{"exercise_price":7.73,"underlying":"Common Stock","underlying_shares":672029},"source":{"system":"sec-edgar","filing":"0000059478-13-000082","document":"wf-form4a_138507260568530.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947813000082/wf-form4a_138507260568530.xml","form_type":"4/A","original_submission_date":"2013-05-14"}},{"id":178836,"issuer":{"id":12658,"kind":"organization","name":"Receptos, Inc.","symbol":"RCPT"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2013-11-21T22:23:39.000Z","date":"2013-05-14","kind":"exercise","acquired":false,"price":0,"reported_value":8640289,"ownership":{"direct":false,"nature":"by Group"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Series A preferred stock and Series B preferred stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of common stock for every 7.5 shares of Series A preferred stock and Series B preferred stock, for no additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A preferred stock and Series B preferred stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of common stock for every 7.5 shares of Series A preferred stock and Series B preferred stock, for no additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A preferred stock and Series B preferred stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of common stock for every 7.5 shares of Series A preferred stock and Series B preferred stock, for no additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund. S. Edward Torres, is a non-managing member of the Fund and may be deemed to beneficially own the shares. Mr. Torres disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein. The attached Exhibit 99.1 lists details for each 10% and beneficial owner."}],"balance_after":0,"derivative":{"exercise_price":5.25,"underlying":"Common Stock","underlying_shares":1152039},"source":{"system":"sec-edgar","filing":"0000059478-13-000082","document":"wf-form4a_138507260568530.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947813000082/wf-form4a_138507260568530.xml","form_type":"4/A","original_submission_date":"2013-05-14"}},{"id":178835,"issuer":{"id":12658,"kind":"organization","name":"Receptos, Inc.","symbol":"RCPT"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-11-21T22:23:39.000Z","date":"2013-05-14","kind":"purchase","acquired":true,"shares":142857,"price":14,"value":1999998.0,"ownership":{"direct":false,"nature":"by Group"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund. S. Edward Torres, is a non-managing member of the Fund and may be deemed to beneficially own the shares. Mr. Torres disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein. The attached Exhibit 99.1 lists details for each 10% and beneficial owner."}],"balance_after":2081210,"source":{"system":"sec-edgar","filing":"0000059478-13-000082","document":"wf-form4a_138507260568530.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947813000082/wf-form4a_138507260568530.xml","form_type":"4/A","original_submission_date":"2013-05-14"}},{"id":178834,"issuer":{"id":12658,"kind":"organization","name":"Receptos, Inc.","symbol":"RCPT"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-11-21T22:23:39.000Z","date":"2013-05-14","kind":"exercise","acquired":true,"shares":672029,"price":7.73,"value":5194784.17,"ownership":{"direct":false,"nature":"by Group"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund. S. Edward Torres, is a non-managing member of the Fund and may be deemed to beneficially own the shares. Mr. Torres disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein. The attached Exhibit 99.1 lists details for each 10% and beneficial owner."}],"balance_after":1938353,"source":{"system":"sec-edgar","filing":"0000059478-13-000082","document":"wf-form4a_138507260568530.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947813000082/wf-form4a_138507260568530.xml","form_type":"4/A","original_submission_date":"2013-05-14"}},{"id":178833,"issuer":{"id":12658,"kind":"organization","name":"Receptos, Inc.","symbol":"RCPT"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12659,"kind":"person","name":"Torres S. Edward","position":3,"cik":"0001552293","reported_name":"Torres S. Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-11-21T22:23:39.000Z","date":"2013-05-14","kind":"exercise","acquired":true,"shares":1152039,"price":5.25,"value":6048204.75,"ownership":{"direct":false,"nature":"by Group"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund. S. Edward Torres, is a non-managing member of the Fund and may be deemed to beneficially own the shares. Mr. Torres disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein. The attached Exhibit 99.1 lists details for each 10% and beneficial owner."}],"balance_after":1266324,"source":{"system":"sec-edgar","filing":"0000059478-13-000082","document":"wf-form4a_138507260568530.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947813000082/wf-form4a_138507260568530.xml","form_type":"4/A","original_submission_date":"2013-05-14"}},{"id":201045,"issuer":{"id":664,"kind":"organization","name":"UNITED THERAPEUTICS Corp","symbol":"UTHR"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2011-07-06T21:14:45.000Z","date":"2011-07-06","kind":"other","acquired":false,"shares":1,"price":43941824.7,"value":43941824.7,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 6, 2011, Eli Lilly and Company (\"Lilly\") settled the first of three tranches of a variable forward contract (the \"Forward Contract\") entered into in September 2010 with an unaffiliated third party (\"Buyer\") , which requires Lilly to deliver to Buyer up to a total of 3,150,838 shares of common stock of United Therapeutics Corporation (\"Common Stock\") in three tranches, beginning with a delivery of up to 1,050,280 shares on July 6, 2011 (the \"First Settlement Date\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(continued from Footnote 1)   Pursuant to the Forward Contract, Lilly was required to deliver a number of shares of Common Stock based on the volume weighted average prices per share of Common Stock on each trading day of the 10 trading day period ending on the date three trading days prior to the First Settlement Date (each, a \"Settlement Price\") and Buyer was required to pay $43,941,824.70.   On July 6, 2011, Lilly delivered 811,443 shares of Common Stock in satisfaction of its obligations under the Forward Contract."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 6, 2011, Eli Lilly and Company (\"Lilly\") settled the first of three tranches of a variable forward contract (the \"Forward Contract\") entered into in September 2010 with an unaffiliated third party (\"Buyer\") , which requires Lilly to deliver to Buyer up to a total of 3,150,838 shares of common stock of United Therapeutics Corporation (\"Common Stock\") in three tranches, beginning with a delivery of up to 1,050,280 shares on July 6, 2011 (the \"First Settlement Date\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from Footnote 1)   Pursuant to the Forward Contract, Lilly was required to deliver a number of shares of Common Stock based on the volume weighted average prices per share of Common Stock on each trading day of the 10 trading day period ending on the date three trading days prior to the First Settlement Date (each, a \"Settlement Price\") and Buyer was required to pay $43,941,824.70.   On July 6, 2011, Lilly delivered 811,443 shares of Common Stock in satisfaction of its obligations under the Forward Contract."}],"balance_after":0,"derivative":{"exercise_date":"2011-07-06","expiration_date":"2011-07-06","underlying":"Common Stock","underlying_shares":811443},"source":{"system":"sec-edgar","filing":"0001209191-11-038423","document":"c19557_4x0.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919111038423/c19557_4x0.xml","form_type":"4"}},{"id":201044,"issuer":{"id":664,"kind":"organization","name":"UNITED THERAPEUTICS Corp","symbol":"UTHR"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2011-07-06T21:14:45.000Z","date":"2011-07-06","kind":"sale","acquired":false,"shares":49103,"price":54.99,"value":2700173.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Forward Contract, any shares not delivered upon settlement were to be returned to Lilly (the \"Extra Shares\"). In connection with the settlement of the first tranche, the parties agreed that the Buyer would pay cash to Lilly in lieu of the Extra Shares being returned to Lilly, with the amount of such cash being determined by  prices based on market prices over a 10-trading day period preceding the First Settlement Date.  Under the terms of this arrangement, Lilly agreed that the Extra Shares would be delivered to Buyer on June 23, 2011, June 29, 2011 and July 6, 2011, and that Lilly would  receive a cash payment for such shares on the First Settlement Date.  Pursuant to the arrangement, 49,103 of the Extra Shares were delivered to Buyer on July 6, 2011, for which Buyer paid $2,700,286.51."}],"balance_after":5251394,"source":{"system":"sec-edgar","filing":"0001209191-11-038423","document":"c19557_4x0.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919111038423/c19557_4x0.xml","form_type":"4"}},{"id":201043,"issuer":{"id":664,"kind":"organization","name":"UNITED THERAPEUTICS Corp","symbol":"UTHR"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2011-07-06T21:14:45.000Z","date":"2011-07-06","kind":"other","acquired":false,"shares":811443,"price":54.15,"value":43939638.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 6, 2011, Eli Lilly and Company (\"Lilly\") settled the first of three tranches of a variable forward contract (the \"Forward Contract\") entered into in September 2010 with an unaffiliated third party (\"Buyer\") , which requires Lilly to deliver to Buyer up to a total of 3,150,838 shares of common stock of United Therapeutics Corporation (\"Common Stock\") in three tranches, beginning with a delivery of up to 1,050,280 shares on July 6, 2011 (the \"First Settlement Date\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from Footnote 1)   Pursuant to the Forward Contract, Lilly was required to deliver a number of shares of Common Stock based on the volume weighted average prices per share of Common Stock on each trading day of the 10 trading day period ending on the date three trading days prior to the First Settlement Date (each, a \"Settlement Price\") and Buyer was required to pay $43,941,824.70.   On July 6, 2011, Lilly delivered 811,443 shares of Common Stock in satisfaction of its obligations under the Forward Contract."}],"balance_after":5251394,"source":{"system":"sec-edgar","filing":"0001209191-11-038423","document":"c19557_4x0.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919111038423/c19557_4x0.xml","form_type":"4"}},{"id":201213,"issuer":{"id":664,"kind":"organization","name":"UNITED THERAPEUTICS Corp","symbol":"UTHR"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2011-07-01T17:53:57.000Z","date":"2011-06-29","kind":"sale","acquired":false,"shares":93991,"price":53.9,"value":5066114.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In September 2010, Eli Lilly and Company (\"Lilly\") entered into a variable forward contract (the \"Forward Contract\") with an unaffiliated third party (\"Buyer\"), which requires Lilly to deliver to Buyer up to a total of 3,150,838 shares of common stock of United Therapeutics Corporation (\"Common Stock\") in three tranches, beginning with a delivery of up to 1,050,280 shares on July 6, 2011 (the \"First Settlement Date\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge.  Under the Forward Contract, the specific number of shares to be delivered is determined by formula, and any shares not delivered were to be returned to Lilly (the \"Extra Shares\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from Footnote 1) In connection with the settlement of the first tranche, the parties agreed that the Buyer would pay cash to Lilly in lieu of  the Extra Shares being returned to Lilly,  with the amount of such cash being determined by prices based on market prices over a 10-trading day period preceding the First Settlement Date.  Under the terms of this arrangement, Lilly agreed that the Extra Shares would be delivered to Buyer on June 23, 2011, June 29, 2011 and July 6, 2011, and that Lilly would  receive a cash payment for such shares on the First Settlement Date.  Pursuant to the arrangement, 95,743 of the Extra Shares were delivered to Buyer on June 23, 2011 and 93,991 of the Extra Shares were delivered to Buyer on June 29, 2011, for which Buyer will be obligated to pay $5,188,833.52 and $5,066,339.39, respectively, on the First Settlement Date."}],"balance_after":6111940,"source":{"system":"sec-edgar","filing":"0001209191-11-037120","document":"c19558_4x0.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919111037120/c19558_4x0.xml","form_type":"4"}},{"id":201212,"issuer":{"id":664,"kind":"organization","name":"UNITED THERAPEUTICS Corp","symbol":"UTHR"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2011-07-01T17:53:57.000Z","date":"2011-06-23","kind":"sale","acquired":false,"shares":95743,"price":54.2,"value":5189270.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In September 2010, Eli Lilly and Company (\"Lilly\") entered into a variable forward contract (the \"Forward Contract\") with an unaffiliated third party (\"Buyer\"), which requires Lilly to deliver to Buyer up to a total of 3,150,838 shares of common stock of United Therapeutics Corporation (\"Common Stock\") in three tranches, beginning with a delivery of up to 1,050,280 shares on July 6, 2011 (the \"First Settlement Date\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge.  Under the Forward Contract, the specific number of shares to be delivered is determined by formula, and any shares not delivered were to be returned to Lilly (the \"Extra Shares\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from Footnote 1) In connection with the settlement of the first tranche, the parties agreed that the Buyer would pay cash to Lilly in lieu of  the Extra Shares being returned to Lilly,  with the amount of such cash being determined by prices based on market prices over a 10-trading day period preceding the First Settlement Date.  Under the terms of this arrangement, Lilly agreed that the Extra Shares would be delivered to Buyer on June 23, 2011, June 29, 2011 and July 6, 2011, and that Lilly would  receive a cash payment for such shares on the First Settlement Date.  Pursuant to the arrangement, 95,743 of the Extra Shares were delivered to Buyer on June 23, 2011 and 93,991 of the Extra Shares were delivered to Buyer on June 29, 2011, for which Buyer will be obligated to pay $5,188,833.52 and $5,066,339.39, respectively, on the First Settlement Date."}],"balance_after":6111940,"source":{"system":"sec-edgar","filing":"0001209191-11-037120","document":"c19558_4x0.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919111037120/c19558_4x0.xml","form_type":"4"}},{"id":211836,"issuer":{"id":664,"kind":"organization","name":"UNITED THERAPEUTICS Corp","symbol":"UTHR"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false,"officer_title":"Director, Chairman and CEO"}}],"security":"Obligation to Sell","published_at":"2010-09-13T20:28:35.000Z","date":"2010-09-09","kind":"other","acquired":true,"shares":1,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Eli Lilly & Company (\"Lilly\") has entered into a variable forward contract (the \"Forward Contract\") with an unaffiliated third party buyer (\"Buyer\") that may obligate Lilly to deliver to Buyer up to 3,150,838 shares of common stock, par value $0.01 per share (\"Common Stock\"), of United Therapeutics Corporation.  The Forward Contract will be settled in three tranches, on July 6, 2011 (the \"First Settlement Date\"), October 5, 2011 (the \"Second Settlement Date\") and December 28, 2011 (the \"Third Settlement Date\", and together with the First Settlement Date and the Second Settlement Date, the \"Settlement Dates\").  (continued in Footnote 2)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The first and second tranches of the Forward Contract each relate to a forward sale of up to 1,050,280 shares of Common Stock, and the third tranche of the Forward Contract relates to a forward sale of up to 1,050,278 shares of Common Stock (each, the \"Maximum Number of Shares\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge. (continued in Footnote 3)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Unless Lilly elects to cash settle the applicable tranche, (i) on each Settlement Date, Lilly will be required to deliver to Buyer a number of shares of Common Stock based on the volume weighted average prices per share of Common Stock on each trading day of the 10 trading day period ending on the date three trading days prior to such Settlement Date (each such price, the \"Settlement Price\") and (ii) Buyer will be required to pay Lilly the product of the Floor Price (as defined below) and the Maximum Number of Shares for such tranche. (continued in Footnote 4)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The number of shares of Common Stock to be delivered by Lilly on each Settlement Date will be determined as follows: (x) if the Settlement Price on a particular trading day during the 10 trading day period is less than or equal to $41.8382 (the \"Floor Price\"), then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10; (y) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the Floor Price but less than or equal to a specified \"Cap Price\" (which is $54.2589 in the case of the First Settlement Date, $54.8229 in the case of the Second Settlement Date, and $54.8819 in the case of the Third Settlement Date), (continued in Footnote 5)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10 multiplied by the Settlement Price divided by the Floor Price, and (z) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the relevant Cap Price, then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares equal divided by 10 multiplied by: [Floor Price + (Settlement Price   Cap Price)] / Settlement Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Eli Lilly & Company (\"Lilly\") has entered into a variable forward contract (the \"Forward Contract\") with an unaffiliated third party buyer (\"Buyer\") that may obligate Lilly to deliver to Buyer up to 3,150,838 shares of common stock, par value $0.01 per share (\"Common Stock\"), of United Therapeutics Corporation.  The Forward Contract will be settled in three tranches, on July 6, 2011 (the \"First Settlement Date\"), October 5, 2011 (the \"Second Settlement Date\") and December 28, 2011 (the \"Third Settlement Date\", and together with the First Settlement Date and the Second Settlement Date, the \"Settlement Dates\").  (continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The first and second tranches of the Forward Contract each relate to a forward sale of up to 1,050,280 shares of Common Stock, and the third tranche of the Forward Contract relates to a forward sale of up to 1,050,278 shares of Common Stock (each, the \"Maximum Number of Shares\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge. (continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Unless Lilly elects to cash settle the applicable tranche, (i) on each Settlement Date, Lilly will be required to deliver to Buyer a number of shares of Common Stock based on the volume weighted average prices per share of Common Stock on each trading day of the 10 trading day period ending on the date three trading days prior to such Settlement Date (each such price, the \"Settlement Price\") and (ii) Buyer will be required to pay Lilly the product of the Floor Price (as defined below) and the Maximum Number of Shares for such tranche. (continued in Footnote 4)"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The number of shares of Common Stock to be delivered by Lilly on each Settlement Date will be determined as follows: (x) if the Settlement Price on a particular trading day during the 10 trading day period is less than or equal to $41.8382 (the \"Floor Price\"), then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10; (y) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the Floor Price but less than or equal to a specified \"Cap Price\" (which is $54.2589 in the case of the First Settlement Date, $54.8229 in the case of the Second Settlement Date, and $54.8819 in the case of the Third Settlement Date), (continued in Footnote 5)"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10 multiplied by the Settlement Price divided by the Floor Price, and (z) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the relevant Cap Price, then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares equal divided by 10 multiplied by: [Floor Price + (Settlement Price   Cap Price)] / Settlement Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Eli Lilly & Company (\"Lilly\") has entered into a variable forward contract (the \"Forward Contract\") with an unaffiliated third party buyer (\"Buyer\") that may obligate Lilly to deliver to Buyer up to 3,150,838 shares of common stock, par value $0.01 per share (\"Common Stock\"), of United Therapeutics Corporation.  The Forward Contract will be settled in three tranches, on July 6, 2011 (the \"First Settlement Date\"), October 5, 2011 (the \"Second Settlement Date\") and December 28, 2011 (the \"Third Settlement Date\", and together with the First Settlement Date and the Second Settlement Date, the \"Settlement Dates\").  (continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The first and second tranches of the Forward Contract each relate to a forward sale of up to 1,050,280 shares of Common Stock, and the third tranche of the Forward Contract relates to a forward sale of up to 1,050,278 shares of Common Stock (each, the \"Maximum Number of Shares\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge. (continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Unless Lilly elects to cash settle the applicable tranche, (i) on each Settlement Date, Lilly will be required to deliver to Buyer a number of shares of Common Stock based on the volume weighted average prices per share of Common Stock on each trading day of the 10 trading day period ending on the date three trading days prior to such Settlement Date (each such price, the \"Settlement Price\") and (ii) Buyer will be required to pay Lilly the product of the Floor Price (as defined below) and the Maximum Number of Shares for such tranche. (continued in Footnote 4)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The number of shares of Common Stock to be delivered by Lilly on each Settlement Date will be determined as follows: (x) if the Settlement Price on a particular trading day during the 10 trading day period is less than or equal to $41.8382 (the \"Floor Price\"), then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10; (y) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the Floor Price but less than or equal to a specified \"Cap Price\" (which is $54.2589 in the case of the First Settlement Date, $54.8229 in the case of the Second Settlement Date, and $54.8819 in the case of the Third Settlement Date), (continued in Footnote 5)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10 multiplied by the Settlement Price divided by the Floor Price, and (z) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the relevant Cap Price, then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares equal divided by 10 multiplied by: [Floor Price + (Settlement Price   Cap Price)] / Settlement Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Eli Lilly & Company (\"Lilly\") has entered into a variable forward contract (the \"Forward Contract\") with an unaffiliated third party buyer (\"Buyer\") that may obligate Lilly to deliver to Buyer up to 3,150,838 shares of common stock, par value $0.01 per share (\"Common Stock\"), of United Therapeutics Corporation.  The Forward Contract will be settled in three tranches, on July 6, 2011 (the \"First Settlement Date\"), October 5, 2011 (the \"Second Settlement Date\") and December 28, 2011 (the \"Third Settlement Date\", and together with the First Settlement Date and the Second Settlement Date, the \"Settlement Dates\").  (continued in Footnote 2)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The first and second tranches of the Forward Contract each relate to a forward sale of up to 1,050,280 shares of Common Stock, and the third tranche of the Forward Contract relates to a forward sale of up to 1,050,278 shares of Common Stock (each, the \"Maximum Number of Shares\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge. (continued in Footnote 3)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Unless Lilly elects to cash settle the applicable tranche, (i) on each Settlement Date, Lilly will be required to deliver to Buyer a number of shares of Common Stock based on the volume weighted average prices per share of Common Stock on each trading day of the 10 trading day period ending on the date three trading days prior to such Settlement Date (each such price, the \"Settlement Price\") and (ii) Buyer will be required to pay Lilly the product of the Floor Price (as defined below) and the Maximum Number of Shares for such tranche. (continued in Footnote 4)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The number of shares of Common Stock to be delivered by Lilly on each Settlement Date will be determined as follows: (x) if the Settlement Price on a particular trading day during the 10 trading day period is less than or equal to $41.8382 (the \"Floor Price\"), then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10; (y) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the Floor Price but less than or equal to a specified \"Cap Price\" (which is $54.2589 in the case of the First Settlement Date, $54.8229 in the case of the Second Settlement Date, and $54.8819 in the case of the Third Settlement Date), (continued in Footnote 5)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10 multiplied by the Settlement Price divided by the Floor Price, and (z) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the relevant Cap Price, then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares equal divided by 10 multiplied by: [Floor Price + (Settlement Price   Cap Price)] / Settlement Price."}],"balance_after":1,"derivative":{"underlying":"Common Stock","underlying_shares":1050278},"source":{"system":"sec-edgar","filing":"0001209191-10-045924","document":"c05869_4x0.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919110045924/c05869_4x0.xml","form_type":"4"}},{"id":211835,"issuer":{"id":664,"kind":"organization","name":"UNITED THERAPEUTICS Corp","symbol":"UTHR"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false,"officer_title":"Director, Chairman and CEO"}}],"security":"Obligation to Sell","published_at":"2010-09-13T20:28:35.000Z","date":"2010-09-09","kind":"other","acquired":true,"shares":1,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Eli Lilly & Company (\"Lilly\") has entered into a variable forward contract (the \"Forward Contract\") with an unaffiliated third party buyer (\"Buyer\") that may obligate Lilly to deliver to Buyer up to 3,150,838 shares of common stock, par value $0.01 per share (\"Common Stock\"), of United Therapeutics Corporation.  The Forward Contract will be settled in three tranches, on July 6, 2011 (the \"First Settlement Date\"), October 5, 2011 (the \"Second Settlement Date\") and December 28, 2011 (the \"Third Settlement Date\", and together with the First Settlement Date and the Second Settlement Date, the \"Settlement Dates\").  (continued in Footnote 2)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The first and second tranches of the Forward Contract each relate to a forward sale of up to 1,050,280 shares of Common Stock, and the third tranche of the Forward Contract relates to a forward sale of up to 1,050,278 shares of Common Stock (each, the \"Maximum Number of Shares\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge. (continued in Footnote 3)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Unless Lilly elects to cash settle the applicable tranche, (i) on each Settlement Date, Lilly will be required to deliver to Buyer a number of shares of Common Stock based on the volume weighted average prices per share of Common Stock on each trading day of the 10 trading day period ending on the date three trading days prior to such Settlement Date (each such price, the \"Settlement Price\") and (ii) Buyer will be required to pay Lilly the product of the Floor Price (as defined below) and the Maximum Number of Shares for such tranche. (continued in Footnote 4)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The number of shares of Common Stock to be delivered by Lilly on each Settlement Date will be determined as follows: (x) if the Settlement Price on a particular trading day during the 10 trading day period is less than or equal to $41.8382 (the \"Floor Price\"), then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10; (y) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the Floor Price but less than or equal to a specified \"Cap Price\" (which is $54.2589 in the case of the First Settlement Date, $54.8229 in the case of the Second Settlement Date, and $54.8819 in the case of the Third Settlement Date), (continued in Footnote 5)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10 multiplied by the Settlement Price divided by the Floor Price, and (z) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the relevant Cap Price, then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares equal divided by 10 multiplied by: [Floor Price + (Settlement Price   Cap Price)] / Settlement Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Eli Lilly & Company (\"Lilly\") has entered into a variable forward contract (the \"Forward Contract\") with an unaffiliated third party buyer (\"Buyer\") that may obligate Lilly to deliver to Buyer up to 3,150,838 shares of common stock, par value $0.01 per share (\"Common Stock\"), of United Therapeutics Corporation.  The Forward Contract will be settled in three tranches, on July 6, 2011 (the \"First Settlement Date\"), October 5, 2011 (the \"Second Settlement Date\") and December 28, 2011 (the \"Third Settlement Date\", and together with the First Settlement Date and the Second Settlement Date, the \"Settlement Dates\").  (continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The first and second tranches of the Forward Contract each relate to a forward sale of up to 1,050,280 shares of Common Stock, and the third tranche of the Forward Contract relates to a forward sale of up to 1,050,278 shares of Common Stock (each, the \"Maximum Number of Shares\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge. (continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Unless Lilly elects to cash settle the applicable tranche, (i) on each Settlement Date, Lilly will be required to deliver to Buyer a number of shares of Common Stock based on the volume weighted average prices per share of Common Stock on each trading day of the 10 trading day period ending on the date three trading days prior to such Settlement Date (each such price, the \"Settlement Price\") and (ii) Buyer will be required to pay Lilly the product of the Floor Price (as defined below) and the Maximum Number of Shares for such tranche. (continued in Footnote 4)"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The number of shares of Common Stock to be delivered by Lilly on each Settlement Date will be determined as follows: (x) if the Settlement Price on a particular trading day during the 10 trading day period is less than or equal to $41.8382 (the \"Floor Price\"), then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10; (y) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the Floor Price but less than or equal to a specified \"Cap Price\" (which is $54.2589 in the case of the First Settlement Date, $54.8229 in the case of the Second Settlement Date, and $54.8819 in the case of the Third Settlement Date), (continued in Footnote 5)"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10 multiplied by the Settlement Price divided by the Floor Price, and (z) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the relevant Cap Price, then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares equal divided by 10 multiplied by: [Floor Price + (Settlement Price   Cap Price)] / Settlement Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Eli Lilly & Company (\"Lilly\") has entered into a variable forward contract (the \"Forward Contract\") with an unaffiliated third party buyer (\"Buyer\") that may obligate Lilly to deliver to Buyer up to 3,150,838 shares of common stock, par value $0.01 per share (\"Common Stock\"), of United Therapeutics Corporation.  The Forward Contract will be settled in three tranches, on July 6, 2011 (the \"First Settlement Date\"), October 5, 2011 (the \"Second Settlement Date\") and December 28, 2011 (the \"Third Settlement Date\", and together with the First Settlement Date and the Second Settlement Date, the \"Settlement Dates\").  (continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The first and second tranches of the Forward Contract each relate to a forward sale of up to 1,050,280 shares of Common Stock, and the third tranche of the Forward Contract relates to a forward sale of up to 1,050,278 shares of Common Stock (each, the \"Maximum Number of Shares\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge. (continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Unless Lilly elects to cash settle the applicable tranche, (i) on each Settlement Date, Lilly will be required to deliver to Buyer a number of shares of Common Stock based on the volume weighted average prices per share of Common Stock on each trading day of the 10 trading day period ending on the date three trading days prior to such Settlement Date (each such price, the \"Settlement Price\") and (ii) Buyer will be required to pay Lilly the product of the Floor Price (as defined below) and the Maximum Number of Shares for such tranche. (continued in Footnote 4)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The number of shares of Common Stock to be delivered by Lilly on each Settlement Date will be determined as follows: (x) if the Settlement Price on a particular trading day during the 10 trading day period is less than or equal to $41.8382 (the \"Floor Price\"), then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10; (y) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the Floor Price but less than or equal to a specified \"Cap Price\" (which is $54.2589 in the case of the First Settlement Date, $54.8229 in the case of the Second Settlement Date, and $54.8819 in the case of the Third Settlement Date), (continued in Footnote 5)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10 multiplied by the Settlement Price divided by the Floor Price, and (z) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the relevant Cap Price, then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares equal divided by 10 multiplied by: [Floor Price + (Settlement Price   Cap Price)] / Settlement Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Eli Lilly & Company (\"Lilly\") has entered into a variable forward contract (the \"Forward Contract\") with an unaffiliated third party buyer (\"Buyer\") that may obligate Lilly to deliver to Buyer up to 3,150,838 shares of common stock, par value $0.01 per share (\"Common Stock\"), of United Therapeutics Corporation.  The Forward Contract will be settled in three tranches, on July 6, 2011 (the \"First Settlement Date\"), October 5, 2011 (the \"Second Settlement Date\") and December 28, 2011 (the \"Third Settlement Date\", and together with the First Settlement Date and the Second Settlement Date, the \"Settlement Dates\").  (continued in Footnote 2)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The first and second tranches of the Forward Contract each relate to a forward sale of up to 1,050,280 shares of Common Stock, and the third tranche of the Forward Contract relates to a forward sale of up to 1,050,278 shares of Common Stock (each, the \"Maximum Number of Shares\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge. (continued in Footnote 3)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Unless Lilly elects to cash settle the applicable tranche, (i) on each Settlement Date, Lilly will be required to deliver to Buyer a number of shares of Common Stock based on the volume weighted average prices per share of Common Stock on each trading day of the 10 trading day period ending on the date three trading days prior to such Settlement Date (each such price, the \"Settlement Price\") and (ii) Buyer will be required to pay Lilly the product of the Floor Price (as defined below) and the Maximum Number of Shares for such tranche. (continued in Footnote 4)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The number of shares of Common Stock to be delivered by Lilly on each Settlement Date will be determined as follows: (x) if the Settlement Price on a particular trading day during the 10 trading day period is less than or equal to $41.8382 (the \"Floor Price\"), then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10; (y) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the Floor Price but less than or equal to a specified \"Cap Price\" (which is $54.2589 in the case of the First Settlement Date, $54.8229 in the case of the Second Settlement Date, and $54.8819 in the case of the Third Settlement Date), (continued in Footnote 5)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10 multiplied by the Settlement Price divided by the Floor Price, and (z) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the relevant Cap Price, then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares equal divided by 10 multiplied by: [Floor Price + (Settlement Price   Cap Price)] / Settlement Price."}],"balance_after":1,"derivative":{"underlying":"Common Stock","underlying_shares":1050280},"source":{"system":"sec-edgar","filing":"0001209191-10-045924","document":"c05869_4x0.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919110045924/c05869_4x0.xml","form_type":"4"}},{"id":211834,"issuer":{"id":664,"kind":"organization","name":"UNITED THERAPEUTICS Corp","symbol":"UTHR"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false,"officer_title":"Director, Chairman and CEO"}}],"security":"Obligation to Sell","published_at":"2010-09-13T20:28:35.000Z","date":"2010-09-09","kind":"other","acquired":true,"shares":1,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Eli Lilly & Company (\"Lilly\") has entered into a variable forward contract (the \"Forward Contract\") with an unaffiliated third party buyer (\"Buyer\") that may obligate Lilly to deliver to Buyer up to 3,150,838 shares of common stock, par value $0.01 per share (\"Common Stock\"), of United Therapeutics Corporation.  The Forward Contract will be settled in three tranches, on July 6, 2011 (the \"First Settlement Date\"), October 5, 2011 (the \"Second Settlement Date\") and December 28, 2011 (the \"Third Settlement Date\", and together with the First Settlement Date and the Second Settlement Date, the \"Settlement Dates\").  (continued in Footnote 2)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The first and second tranches of the Forward Contract each relate to a forward sale of up to 1,050,280 shares of Common Stock, and the third tranche of the Forward Contract relates to a forward sale of up to 1,050,278 shares of Common Stock (each, the \"Maximum Number of Shares\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge. (continued in Footnote 3)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Unless Lilly elects to cash settle the applicable tranche, (i) on each Settlement Date, Lilly will be required to deliver to Buyer a number of shares of Common Stock based on the volume weighted average prices per share of Common Stock on each trading day of the 10 trading day period ending on the date three trading days prior to such Settlement Date (each such price, the \"Settlement Price\") and (ii) Buyer will be required to pay Lilly the product of the Floor Price (as defined below) and the Maximum Number of Shares for such tranche. (continued in Footnote 4)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The number of shares of Common Stock to be delivered by Lilly on each Settlement Date will be determined as follows: (x) if the Settlement Price on a particular trading day during the 10 trading day period is less than or equal to $41.8382 (the \"Floor Price\"), then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10; (y) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the Floor Price but less than or equal to a specified \"Cap Price\" (which is $54.2589 in the case of the First Settlement Date, $54.8229 in the case of the Second Settlement Date, and $54.8819 in the case of the Third Settlement Date), (continued in Footnote 5)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10 multiplied by the Settlement Price divided by the Floor Price, and (z) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the relevant Cap Price, then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares equal divided by 10 multiplied by: [Floor Price + (Settlement Price   Cap Price)] / Settlement Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Eli Lilly & Company (\"Lilly\") has entered into a variable forward contract (the \"Forward Contract\") with an unaffiliated third party buyer (\"Buyer\") that may obligate Lilly to deliver to Buyer up to 3,150,838 shares of common stock, par value $0.01 per share (\"Common Stock\"), of United Therapeutics Corporation.  The Forward Contract will be settled in three tranches, on July 6, 2011 (the \"First Settlement Date\"), October 5, 2011 (the \"Second Settlement Date\") and December 28, 2011 (the \"Third Settlement Date\", and together with the First Settlement Date and the Second Settlement Date, the \"Settlement Dates\").  (continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The first and second tranches of the Forward Contract each relate to a forward sale of up to 1,050,280 shares of Common Stock, and the third tranche of the Forward Contract relates to a forward sale of up to 1,050,278 shares of Common Stock (each, the \"Maximum Number of Shares\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge. (continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Unless Lilly elects to cash settle the applicable tranche, (i) on each Settlement Date, Lilly will be required to deliver to Buyer a number of shares of Common Stock based on the volume weighted average prices per share of Common Stock on each trading day of the 10 trading day period ending on the date three trading days prior to such Settlement Date (each such price, the \"Settlement Price\") and (ii) Buyer will be required to pay Lilly the product of the Floor Price (as defined below) and the Maximum Number of Shares for such tranche. (continued in Footnote 4)"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The number of shares of Common Stock to be delivered by Lilly on each Settlement Date will be determined as follows: (x) if the Settlement Price on a particular trading day during the 10 trading day period is less than or equal to $41.8382 (the \"Floor Price\"), then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10; (y) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the Floor Price but less than or equal to a specified \"Cap Price\" (which is $54.2589 in the case of the First Settlement Date, $54.8229 in the case of the Second Settlement Date, and $54.8819 in the case of the Third Settlement Date), (continued in Footnote 5)"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10 multiplied by the Settlement Price divided by the Floor Price, and (z) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the relevant Cap Price, then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares equal divided by 10 multiplied by: [Floor Price + (Settlement Price   Cap Price)] / Settlement Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Eli Lilly & Company (\"Lilly\") has entered into a variable forward contract (the \"Forward Contract\") with an unaffiliated third party buyer (\"Buyer\") that may obligate Lilly to deliver to Buyer up to 3,150,838 shares of common stock, par value $0.01 per share (\"Common Stock\"), of United Therapeutics Corporation.  The Forward Contract will be settled in three tranches, on July 6, 2011 (the \"First Settlement Date\"), October 5, 2011 (the \"Second Settlement Date\") and December 28, 2011 (the \"Third Settlement Date\", and together with the First Settlement Date and the Second Settlement Date, the \"Settlement Dates\").  (continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The first and second tranches of the Forward Contract each relate to a forward sale of up to 1,050,280 shares of Common Stock, and the third tranche of the Forward Contract relates to a forward sale of up to 1,050,278 shares of Common Stock (each, the \"Maximum Number of Shares\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge. (continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Unless Lilly elects to cash settle the applicable tranche, (i) on each Settlement Date, Lilly will be required to deliver to Buyer a number of shares of Common Stock based on the volume weighted average prices per share of Common Stock on each trading day of the 10 trading day period ending on the date three trading days prior to such Settlement Date (each such price, the \"Settlement Price\") and (ii) Buyer will be required to pay Lilly the product of the Floor Price (as defined below) and the Maximum Number of Shares for such tranche. (continued in Footnote 4)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The number of shares of Common Stock to be delivered by Lilly on each Settlement Date will be determined as follows: (x) if the Settlement Price on a particular trading day during the 10 trading day period is less than or equal to $41.8382 (the \"Floor Price\"), then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10; (y) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the Floor Price but less than or equal to a specified \"Cap Price\" (which is $54.2589 in the case of the First Settlement Date, $54.8229 in the case of the Second Settlement Date, and $54.8819 in the case of the Third Settlement Date), (continued in Footnote 5)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10 multiplied by the Settlement Price divided by the Floor Price, and (z) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the relevant Cap Price, then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares equal divided by 10 multiplied by: [Floor Price + (Settlement Price   Cap Price)] / Settlement Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Eli Lilly & Company (\"Lilly\") has entered into a variable forward contract (the \"Forward Contract\") with an unaffiliated third party buyer (\"Buyer\") that may obligate Lilly to deliver to Buyer up to 3,150,838 shares of common stock, par value $0.01 per share (\"Common Stock\"), of United Therapeutics Corporation.  The Forward Contract will be settled in three tranches, on July 6, 2011 (the \"First Settlement Date\"), October 5, 2011 (the \"Second Settlement Date\") and December 28, 2011 (the \"Third Settlement Date\", and together with the First Settlement Date and the Second Settlement Date, the \"Settlement Dates\").  (continued in Footnote 2)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The first and second tranches of the Forward Contract each relate to a forward sale of up to 1,050,280 shares of Common Stock, and the third tranche of the Forward Contract relates to a forward sale of up to 1,050,278 shares of Common Stock (each, the \"Maximum Number of Shares\").  Lilly pledged 3,150,838 shares of Common Stock to secure its obligations under the Forward Contract and retained dividend and voting rights in such shares during the term of the pledge. (continued in Footnote 3)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Unless Lilly elects to cash settle the applicable tranche, (i) on each Settlement Date, Lilly will be required to deliver to Buyer a number of shares of Common Stock based on the volume weighted average prices per share of Common Stock on each trading day of the 10 trading day period ending on the date three trading days prior to such Settlement Date (each such price, the \"Settlement Price\") and (ii) Buyer will be required to pay Lilly the product of the Floor Price (as defined below) and the Maximum Number of Shares for such tranche. (continued in Footnote 4)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The number of shares of Common Stock to be delivered by Lilly on each Settlement Date will be determined as follows: (x) if the Settlement Price on a particular trading day during the 10 trading day period is less than or equal to $41.8382 (the \"Floor Price\"), then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10; (y) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the Floor Price but less than or equal to a specified \"Cap Price\" (which is $54.2589 in the case of the First Settlement Date, $54.8229 in the case of the Second Settlement Date, and $54.8819 in the case of the Third Settlement Date), (continued in Footnote 5)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares divided by 10 multiplied by the Settlement Price divided by the Floor Price, and (z) if the Settlement Price on a particular trading day during the 10 trading day period is greater than the relevant Cap Price, then with respect to such trading day, Lilly will be required to deliver a number of shares of Common Stock equal to the Maximum Number of Shares equal divided by 10 multiplied by: [Floor Price + (Settlement Price   Cap Price)] / Settlement Price."}],"balance_after":1,"derivative":{"underlying":"Common Stock","underlying_shares":1050280},"source":{"system":"sec-edgar","filing":"0001209191-10-045924","document":"c05869_4x0.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000120919110045924/c05869_4x0.xml","form_type":"4"}},{"id":281894,"issuer":{"id":13934,"kind":"organization","name":"ICAGEN INC","symbol":"ICGN"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2005-02-10T18:57:08.000Z","date":"2005-02-08","kind":"exercise","acquired":false,"shares":125340,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's public offering, the Series B Convertible Preferred Stock converted on a 1-for-1 basis into Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's public offering, the Series B Convertible Preferred Stock converted on a 1-for-1 basis into Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These shares were immediately exercisable.  They had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These shares were immediately exercisable.  They had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":125340},"source":{"system":"sec-edgar","filing":"0001181431-05-008570","document":"rrd66558.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000118143105008570/rrd66558.xml","form_type":"4"}},{"id":281893,"issuer":{"id":13934,"kind":"organization","name":"ICAGEN INC","symbol":"ICGN"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2005-02-10T18:57:08.000Z","date":"2005-02-08","kind":"exercise","acquired":true,"shares":125340,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's public offering, the Series B Convertible Preferred Stock converted on a 1-for-1 basis into Common Stock."}],"balance_after":300340,"source":{"system":"sec-edgar","filing":"0001181431-05-008570","document":"rrd66558.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000118143105008570/rrd66558.xml","form_type":"4"}}]}